Krsnaa Diagnostics Reports 22% Profit Surge in Q2 FY26, Driven by Margin Expansion
Krsnaa Diagnostics achieved record quarterly profit after tax of INR 239.00 million in Q2 FY26, up 22% year-over-year. Revenue increased by 11% to INR 2,060.00 million, while EBITDA grew 18% to INR 602.00 million. The company expanded its NABL-accredited pathology labs by 54% and NABH-accredited radiology centers by 50%. Retail revenue surged from INR 16.00 million to INR 174.00 million, now contributing 8% to group revenue. Krsnaa operates in 18 states and union territories, with 186 CT/MRI centers and 120 pathology labs. The company continues to offer diagnostic services at rates approximately 70% below market prices.
*this image is generated using AI for illustrative purposes only.
Krsnaa Diagnostics , one of India's largest integrated diagnostic service providers, has reported a robust financial performance for the second quarter of fiscal year 2026, showcasing significant growth across key metrics.
Financial Highlights
The company achieved an all-time high quarterly profit after tax (PAT) of INR 239.00 million, marking a substantial 22% year-over-year increase from INR 196.00 million in Q2 FY25. This growth was primarily driven by strengthening margins and improved operating leverage.
Here's a breakdown of Krsnaa Diagnostics' Q2 FY26 financial performance:
| Metric | Q2 FY26 | Q2 FY25 | Growth |
|---|---|---|---|
| Revenue | 2,060.00 | 1,863.00 | 11% |
| EBITDA | 602.00 | 509.00 | 18% |
| EBITDA Margin | 29% | 27% | 221 bps |
| PAT | 239.00 | 196.00 | 22% |
| PAT Margin | 12% | 11% | 111 bps |
| EPS | 7.30 | 5.90 | 24% |
Operational Performance
Krsnaa Diagnostics continued to expand its reach and enhance its service offerings:
- Served 5.4 million patients in Q2 FY26, a 4% increase from the previous year
- Performed 16.4 million tests, slightly down by 4% compared to Q2 FY25
- Increased NABL-accredited pathology labs to 57, up 54% from 37 in Q2 FY25
- Expanded NABH-accredited radiology centers to 36, a 50% growth from 24 in the previous year
Retail Business Growth
The company's retail segment showed remarkable progress:
- Retail revenue surged to INR 174.00 million in Q2 FY26, up from INR 16.00 million in Q2 FY25
- Retail revenue contribution to group revenue increased from 1% to 8% year-over-year
- Number of retail touch points grew significantly from 5 to 2,878
Expanding Footprint
Krsnaa Diagnostics has strengthened its presence across India:
- Operates in 18 states and union territories
- Runs 186 CT/MRI centers and 120 pathology labs
- Manages over 3,500 patient collection centers
Future Outlook
The company's existing order book is set to expand its network to over 200 CT/MRI centers, potentially making it one of Asia's largest radiology players. Additionally, the Rajasthan project is expected to significantly boost Krsnaa's pathology network, enhancing its accessibility across India.
Commitment to Affordable Healthcare
Krsnaa Diagnostics continues to offer diagnostic services at rates approximately 70% below market prices across radiology, pathology, and tele-radiology services through its public-private partnership model. This approach has enabled the company to serve over 75 million patients since its inception, making quality healthcare more accessible to a broader population.
As Krsnaa Diagnostics maintains its growth trajectory, it demonstrates that providing affordable diagnostic services can go hand-in-hand with strong financial performance and market expansion.
Historical Stock Returns for Krsnaa Diagnostics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.52% | -0.71% | +1.90% | +26.47% | -19.05% | -17.86% |
20
